← Back to Search

Hormone Therapy

Estrogen Modulation for Menopause Mood and Cognition

Phase 2

Waitlist Available

Research Sponsored by National Center for Research Resources (NCRR)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Postmenopausal

Not on hormone replacement therapy (HRT) or more than 1 year post HRT

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will study the effects of estrogen on women's brain chemistry, specifically how it affects their mood in response to dietary changes.

Who is the study for?

This trial is for healthy, non-smoking postmenopausal women aged 50-60 and those over 70. Participants must have a BMI under 30, not be on hormone replacement therapy (HRT) or more than a year past HRT, have had a normal mammogram in the last year, and cannot have surgically-induced menopause or cardiovascular disease.Check my eligibility

What is being tested?

The study tests if estrogen can affect mood and brain chemistry changes caused by diet in postmenopausal women. Women will take either estrogen or placebo for three months before undergoing dietary challenges to alter neurotransmitters like serotonin.See study design

What are the potential side effects?

While specific side effects are not listed here, generally estrogen treatment may include risks such as headaches, breast tenderness, nausea, mood swings, and blood clotting issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have gone through menopause.

Select...

I am not currently on hormone replacement therapy and have not been for over a year.

Select...

I have not had surgery to remove my ovaries.

Select...

I only have mild high blood pressure, no other heart conditions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Center for Research Resources (NCRR)Lead Sponsor

537 Previous Clinical Trials

317,016 Total Patients Enrolled

2 Trials studying Menopause

15 Patients Enrolled for Menopause

Media Library

Estrogen (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT00005768 — Phase 2

Menopause Clinical Trial 2023: Estrogen Highlights & Side Effects. Trial Name: NCT00005768 — Phase 2

Estrogen (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00005768 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research involve any individuals above the age of seventy?

"Individuals that meet the age requirement of 50 to 0 are eligible for this particular trial. There are 5 other trials available for those under 18 and 21 more for patients over 65 years old."

Answered by AI

Has this medication received regulatory approval from the FDA?

"While there is some data suggesting this intervention is safe, it only exists in a Phase 2 trial. This means that, currently, there is no evidence to support its efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Estrogen Modulation of Mood and Cognition Following Monoaminergic Depletion in Post-Menopausal Women

2024. "Estrogen Modulation of Mood and Cognition Following Monoaminergic Depletion in Post-Menopausal Women". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00005768.

All > Vermont > Menopause